EUVIMEDEUVIMED entdecken
Crossref

An RNA Aptamer Targeting PAI-1 That Restores tPA Activity, Unexpectedly Suppresses Cancer Cell Progression

Christopher Hu, Austin Schneidler, Mamadou Barry, Michelle Gimba, Sihan Zhou, Yolanda M Fortenberry

Nucleic Acid Therapeutics · 2025

DOI: 10.1177/21593337251404397 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nucleic Acid Therapeutics, 2025. Verfasst von Christopher Hu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Biology Department Case, Western Reserve University, Cleveland, OH, USA. Hauptthemen laut MEDLINE: Aptamers, Nucleotide, Plasminogen Activator Inhibitor 1, Tissue Plasminogen Activator, Triple Negative Breast Neoplasms. Die Arbeit nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Plasminogen activator inhibitor-1 (PAI-1), the primary physiological inhibitor of tissue-type plasminogen activator (tPA), is a key regulator of fibrinolysis. Elevated levels of PAI-1 are linked to thrombotic disorders and correlate with poor prognosis across various cancers. In this study, we further characterize the RNA aptamer R10-4, previously shown to bind PAI-1 with high affinity and inhibit its antiproteolytic activity. While R10-4’s role in modulating fibrinolysis is established, its influence on cancer cell behavior remains unclear. Here, we demonstrate that intracellular transfection of R10-4 in triple negative breast cancer cells significantly impairs migration and invasion without affecting proliferation, mirroring the effects observed with other PAI-1–specific RNA aptamers. Moreover, conditioned media from R10-4 transfected cells suppress endothelial tube formation and exhibit reduced secretion of the pro-angiogenic chemokine (C-C) motif ligand 5 (CCL5). Collectively, these findings reveal that R10-4 restores fibrinolytic balance and disrupts PAI-1–mediated tumor progression, positioning it as a promising multifunctional candidate for therapeutic development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aptamers, NucleotidePlasminogen Activator Inhibitor 1Tissue Plasminogen ActivatorTriple Negative Breast NeoplasmsHumansCell MovementCell Line, TumorFemaleCell ProliferationChemokine CCL5FibrinolysisDisease Progression

Stichwörter der Autor:innen

RNAangiogenesisaptamersbreast cancercancercell invasioncell migration

Substanzen

Aptamers, NucleotidePlasminogen Activator Inhibitor 1Tissue Plasminogen ActivatorSERPINE1 protein, humanChemokine CCL5

Autor:innen und Institutionen

  • Biology Department Case, Western Reserve University, Cleveland, OH, USA.
  • Division of Pediatric Hematology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Zitieren

APA

Hu, C., Schneidler, A., Barry, M., Gimba, M., Zhou, S., & Fortenberry, Y. M. (2025). An RNA Aptamer Targeting PAI-1 That Restores tPA Activity, Unexpectedly Suppresses Cancer Cell Progression. Nucleic Acid Therapeutics. https://doi.org/10.1177/21593337251404397

Vancouver

Hu C, Schneidler A, Barry M, Gimba M, Zhou S, Fortenberry YM. An RNA Aptamer Targeting PAI-1 That Restores tPA Activity, Unexpectedly Suppresses Cancer Cell Progression. Nucleic Acid Therapeutics. 2025. doi:10.1177/21593337251404397

BibTeX
@article{Hu2025,
  author = {Hu, Christopher and Schneidler, Austin and Barry, Mamadou and Gimba, Michelle and Zhou, Sihan and Fortenberry, Yolanda M},
  title = {An RNA Aptamer Targeting PAI-1 That Restores tPA Activity, Unexpectedly Suppresses Cancer Cell Progression},
  journal = {Nucleic Acid Therapeutics},
  year = {2025},
  doi = {10.1177/21593337251404397}
}
Kostenlos starten →